This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synthetic Biologics Enters Into License With Cedars-Sinai Medical Center To Develop Novel Anti-infective Approaches For Irritable Bowel Syndrome (IBS), Obesity And Diabetes

ROCKVILLE, Md., Dec. 7, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious diseases and other diseases, announced today that it entered into worldwide license and option agreements with Cedars-Sinai Medical Center ("Cedars-Sinai") for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, through its newly formed subsidiary, Synthetic Biomics, Inc.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO )

Cedars-Sinai investigators have discovered that eradicating archaea and inhibiting intestinal methane production may treat the underlying cause of major diseases not typically considered forms of infectious diseases. IBS, one of the most prevalent chronic diseases, affects approximately 40 million Americans (an estimated 16 million of which have the archaea-associated constipation-predominant form of the disease (C-IBS)). Obesity affects over one-third (35.7%) of adult Americans according to the Centers for Disease Control (CDC). Diabetes affects an estimated 25.8 million Americans according to the CDC.

Ongoing efforts include formulating and clinically testing non-antibiotic FDA-approved oral drug candidates for ultimate product registration via potential expedited pathways. Such candidates are intended for the specific eradication of gastrointestinal archaea and prevention of their recolonization, with the goal of having little or no impact on a patient's normal bacterial microflora. These efforts are being led by Mark Pimentel, M.D., FRCP(C), Director of the Gastrointestinal Motility Program at Cedars-Sinai Medical Center, who is credited with discovering that IBS is a form of infectious disease, in which gut microflora that should normally be confined to the large intestine inappropriately colonize the small intestine. This process is referred to as small intestinal bacterial overgrowth (SIBO), which results in gas, bloating, abdominal pain and altered stool habits characterized by IBS. The Company licensed and optioned from Cedars-Sinai a portfolio of intellectual property comprised of several U.S. and international patents and pending patent applications for various fields of use, including C-IBS, obesity and diabetes.

"We are pleased to initiate this exciting new anti-infective approach to treat these major archaea-implicated disease indications with Cedars-Sinai along with Dr. Pimentel's leadership," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics, Inc. "This program complements our current microbiome focus and expertise, which includes development of an oral biologic to protect the microbiome from the effects of hospital administered IV antibiotics for the prevention of C. diff infection."

Dr. Pimentel stated, "Since uncovering the fundamental role that small intestinal bacterial overgrowth plays in IBS, our group has continued to uncover and increasingly appreciate the role that intestinal archaea play in highly prevalent diseases areas including, C-IBS, obesity, and type 2 diabetes. I am excited to be working with Synthetic Biologics and its newly formed subsidiary, Synthetic Biomics, to develop potential breakthrough pathogen-specific approaches for these major disease indications."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs